The invention relates to a solid pharmaceutical composition comprising rivaroxaban, or a pharmaceutically acceptable salt or solvate thereof, and at least one pharmaceutically acceptable excipient. The invention also relates to a process for the preparation of a solid pharmaceutical composition comprising rivaroxaban, or a pharmaceutically acceptable salt or solvate thereof, the process comprising (a) providing a mixture comprising rivaroxaban and at least one pharmaceutically acceptable excipient and (b) converting said mixture to a solid pharmaceutical composition.

The subject of the invention includes a pharmaceutical composition comprising micronized prasugrel or its pharmaceutically acceptable salts as the active pharmaceutical ingredient, prepared in the absence of water with solvent 5 free technological methods and characterized in that it does not contain lactose.